Abbott ABT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Diagnostic Products | $9.06B-1.3% | $8.94B-4.3% | $9B-3.8% | $9.16B-2.5% | $9.18B-3.5% | |
| Established Pharmaceuticals | $5.7B+9.1% | $5.54B+6.6% | $5.42B+5.3% | $5.32B+4.1% | $5.23B+2.4% | |
| Medical Devices | $22.03B+13.4% | $21.39B+12.6% | $20.76B+13.0% | $20.06B+12.2% | $19.43B+11.4% | |
| Nutritional Products | $8.32B-2.0% | $8.45B+0.5% | $8.64B+3.8% | $8.55B+2.7% | $8.49B+2.9% | |
| Total Assets by Business | ||||||
| Diagnostic Products | $34.28B— | $32.49B— | $31.9B— | —— | —— | |
| Established Pharmaceuticals | $14.67B— | $14.45B— | $14B— | —— | —— | |
| Medical Devices | $42.8B— | $41.85B— | $40.64B— | —— | —— | |
| Nutritional Products | $19.5B— | $19.23B— | $18.84B— | —— | —— | |
| Operating Earnings by Business | ||||||
| Diagnostic Products | $1.72B-12.4% | $1.74B-16.1% | $1.74B-19.9% | $1.9B-15.5% | $1.96B-13.2% | |
| Established Pharmaceuticals | $1.36B+7.4% | $1.29B+4.6% | $1.31B+7.4% | $1.3B+9.7% | $1.26B+7.8% | |
| Medical Devices | $7.5B+17.1% | $7.21B+17.2% | $7.01B+19.1% | $6.69B+17.2% | $6.4B+14.6% | |
| Nutritional Products | $1.48B-3.1% | $1.56B+3.5% | $1.62B+13.5% | $1.57B+12.3% | $1.52B+14.4% | |
| Selling, general, and administrative by Business | ||||||
| Diagnostic Products | $1.67B+3.4% | $1.61B-0.4% | $1.64B+2.2% | $1.64B+2.6% | $1.61B+1.3% | |
| Established Pharmaceuticals | $1.48B+9.0% | $1.46B+8.5% | $1.41B+4.3% | $1.38B+2.5% | $1.36B+2.0% | |
| Medical Devices | $5.55B+11.3% | $5.45B+11.7% | $5.32B+12.6% | $5.15B+11.8% | $4.99B+11.1% | |
| Nutritional Products | $2.1B-4.3% | $2.11B-2.6% | $2.17B-1.9% | $2.2B+0.6% | $2.19B+2.3% | |
| Cost of products sold, excluding amortization of intangible assets by Business | ||||||
| Diagnostic Products | -$4.89B+2.7% | -$4.98B+0.2% | -$5B-312% | -$5.01B-1,979% | -$5.03B-82.3% | |
| Established Pharmaceuticals | -$2.54B-3.3% | -$2.62B-7.0% | -$2.35B-291% | -$2.42B-69,014% | -$2.46B-108% | |
| Medical Devices | -$6.76B-6.3% | -$6.97B-8.8% | -$6.06B-282% | -$6.23B-2,385% | -$6.36B-127% | |
| Nutritional Products | -$4.6B-2.4% | -$4.57B-0.8% | -$4.42B-295% | -$4.49B-38,935% | -$4.5B-96.9% | |
| R&D by Business | ||||||
| Diagnostic Products | $606M-7.1% | $602M-8.2% | $629M-4.2% | $644M-3.3% | $652M-3.9% | |
| Established Pharmaceuticals | $175M-1.1% | $176M0.0% | $172M-1.3% | $176M+2.6% | $177M+3.7% | |
| Medical Devices | $1.8B+13.7% | $1.75B+13.4% | $1.68B+12.6% | $1.63B+14.1% | $1.58B+13.6% | |
| Nutritional Products | $215M+2.9% | $213M+1.9% | $212M+1.4% | $210M+1.4% | $209M+2.0% | |
| Additions to Property and Equipment by Business | ||||||
| Diagnostic Products | $754M-2.1% | $761M+0.4% | $752M+13.5% | $767M+15.0% | $770M+12.3% | |
| Established Pharmaceuticals | $156M-16.6% | $169M-7.7% | $175M+6.5% | $189M+19.2% | $187M+11.5% | |
| Medical Devices | $649M-0.3% | $658M+4.4% | $627M+5.4% | $638M+7.2% | $651M+10.7% | |
| Nutritional Products | $263M-32.2% | $302M-20.9% | $331M-16.5% | $366M-9.5% | $388M-6.7% | |
| Remaining performance obligations by Business | ||||||
| Diagnostic Products | $24.2B+13.6% | $23.7B+17.9% | $23.1B+21.6% | $22.4B+25.1% | $21.3B+23.1% | |
| Medical Devices | $1.74B-4.7% | $1.73B-8.7% | $1.73B-10.7% | $1.76B-8.6% | $1.82B-4.3% | |
| Depreciation by Business | ||||||
| Diagnostic Products | $551M+6.4% | $533M+2.3% | $531M+3.8% | $524M+3.3% | $518M+2.9% | |
| Established Pharmaceuticals | $108M+13.7% | $101M+5.2% | $101M+4.1% | $96M-4.0% | $95M-6.9% | |
| Medical Devices | $390M+13.4% | $378M+10.2% | $361M+6.3% | $351M+5.9% | $344M+6.4% | |
| Nutritional Products | $183M+13.0% | $175M+10.1% | $176M+13.7% | $167M+7.4% | $162M+4.3% | |
| Goodwill, non-deductible by Business | ||||||
| Diagnostic Products | $25.7B+82.3% | $14.3B+1.4% | $14.2B0.0% | $14.2B+0.7% | $14.1B0.0% | |
| Established Pharmaceuticals | $10.8B+2.9% | $10.7B+0.9% | $10.6B-0.9% | $10.6B0.0% | $10.5B-1.9% | |
| Medical Devices | $69.4B+2.5% | $69B+1.9% | $68.4B+0.6% | $68.1B+0.6% | $67.7B+0.3% | |
| Nutritional Products | $1.16B+1.3% | $1.14B0.0% | $1.14B0.0% | $1.14B0.0% | $1.14B-0.1% | |
| Net Sales by Geography | ||||||
| International | $27.9B+8.6% | $27.2B+6.1% | $26.76B+5.8% | $26.12B+3.7% | $25.7B+3.0% | |
| United States | $17.23B+3.5% | $17.13B+4.9% | $17.08B+7.2% | $16.99B+9.3% | $16.65B+8.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Abbott break its business down?
- Abbott (ABT) reports net sales by business across 4 parts — Diagnostic Products, Established Pharmaceuticals, Medical Devices and Nutritional Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Abbott's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Abbott's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
